BIOA as reported
BioAge Labs, Inc. reported $10M of revenue over the trailing twelve months, +611% on the year before. 9 reported series are charted on this page, each one as filed.
$10M
Revenue, trailing twelve months · to Q1 2026 · +611% against the twelve months before
- Net Income
- −$90M
Net Income · +27% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$89M
Free Cash Flow · +64% year on year · trailing twelve months to Q1 2026
- Op Margin
- −998%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $10M | +611% | Q1 2026 |
| Net Income | −$90M | +27% | Q1 2026 |
| EPS | −$2.40 | −1946% | Q1 2026 |
| Op Margin | −998% | n/a | Q1 2026 |
| Net Margin | −880% | n/a | Q1 2026 |
| ROE | −27% | n/a | Q1 2026 |
| ROA | −25% | n/a | Q1 2026 |
| ROIC | 3601% | n/a | Q1 2026 |
| Free Cash Flow | −$89M | +64% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
BioAge Labs, Inc. (BIOA) - Revenue & ProfitRevenue & ProfitBioAge Labs, Inc. (BIOA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry